Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupPlasma cell neoplasmsDiseaseAmyloidosisSubgroupAL AmyloidosisICD10E85.-MeSHAmyloidosisSequenceANDROMEDA: DEXA(20/20)/CYCL300/DRTM1800/BORT1,3, AL amyloidosis, C1-2 (PID1631) -|- C3-6 (PID1632) -|-C7+ (PID1633)DEXA40/MELP0.22/BORT1.3, AL-Amyloidosis, C1-2 (PID1638) -|- C3-8 (PID1639)DRTM(8/8/16), AL amyloidosis, C1 (PID1473) -|- C2 (PID1478) -|- C3-6 (PID1479) -|- C7+ (PID1480)DRTM(8/8/16)/LENA5/DEXA20, AL amyloidosis, C1 (PID2444) -|- C2 (PID2445) -|- C3-6 (PID2446) -|- C7+ (PID2447)DRTM1800/BORT1.0/DEXA20, AL-Amyloidosis, C1-2 (PID2456) -|- C3-6 (PID2457) -|- C7+ (PID2458).DRTM1800/LENA5/DEXA20, AL-Amyloidosis, C1-2 (PID2452) -|- C3-6 (PID2453) -|- C7+ (PID2454)ChemotherapyChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanChemo-substanceBendamustineBortezomibCyclophosphamideDaratumumabDexamethasoneIxazomibLenalidomideMelphalanNo. Substances1234 RadiotherapySupportive therapySupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneSupportive substanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDalteparinDexamethasoneDimetindenFilgrastimGranisetronItraconazoleMontelukastPantoprazoleParacetamolPrednisoloneNo. Substances1234568910Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlAstheniaAtrial FibrillationBleedingCardiotoxicityColitisConstipationDiarrheaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Heart FailureHepatotoxicityHypertensionHypokalemiaHyponatremiaHypotensionInfectionsInfusion ReactionLeukopeniaLymphopeniaNeuropathyNeurotoxicityNeutropeniaPneumoniaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorCohen OC Dietrich SDispenzieri A Hegenbart UKastritis EKimmich CRLentzsch SPalladini GReece DSanchorawala VVenner CPDiseaseAL-AmyloidoseAL-Amyloidose, mindestens 1 Vortherapie, ECOG 0-2AL-Amyloidose, neu diagnostiziertAL-Amyloidose, neu diagnostiziert, ECOG 0-2AL-Amyloidose, neu diagnostiziert, nicht geeignet für ASCTAL-Amyloidose, neu diagnostiziert oder rezidiviertAL-Amyloidose, nicht für ASCT geeignet, mindestens 1 Vortherapie, ECOG 0-2AL-Amyloidose, nicht vorbehandelt, nicht geeignet für ASCTAL-Amyloidose, rezidiviert oder therapierefraktär, 1-2 VortherapienAL-Amyloidose, therapierefraktär oder rezidiviertAL-Amyloidose, vorbehandeltAL-Amyloidose, vorbehandelt, ECOG 0-1, Kreatinin-Clearance über 40 ml/min, EF über 40%AL-Amyloidose ohne fortgeschrittene kardiale Beteiligung (Stadium IIIb nach Mayo 2004/European cardiac staging system), nicht geeignet für eine ASCTNeu diagnostizierte AL-Amyloidose, nicht geeignet für ASCTOriginAmyloidosis Research and Treatment Center, Pavia, Italy, ANDROMEDA trialBoston University School of Medicine, United StatesColumbia University Medical Center, New York, USADivision of Hematology, Mayo Clinic, Rochester, NY, USA, TOURMALINE-AL1Heidelberg University Hospital, Heidelberg, GermanyNational Amyloidosis Centre, University College London (Royal Free Campus), London, UKNational and Kapodistrian University of Athens, School of Medicine, Athens, GreecePrincess Margaret Hospital, Toronto, CanadaUniversity College London Medical School, London, United KingdomUniversity Hospital Pavia and University of Pavia, ItalyUniversity of Athens School of Medicine, Athens, GreeceUniversity of Heidelberg, Heidelberg, GermanyProtocols in Revision 29 protocols foundProtocols under revision.Bortezomib 1,3, AL Amyloidosis (PID1510)Bortezomib 1.6, AL Amyloidosis (PID1509)Daratumumab (8/8/16) / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 1 (PID2444)Daratumumab (8/8/16), AL amyloidosis, cycle 1 (PID1473)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 2 (PID2445)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 3-6 (PID2446)Daratumumab 16 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 7+ (PID2447)Daratumumab 16, AL amyloidosis, cycle 2 (PID1478)Daratumumab 16, AL Amyloidosis, cycle 3-6 (PID1479)Daratumumab 16, AL amyloidosis, cycle 7+ (PID1480)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20 - Daratumumab 1800 maintenance, AL-Amyloidosis, cycle 7+. (PID2458)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20, AL-Amyloidosis, cycle 1-2. (PID2456)Daratumumab 1800 / Bortezomib 1.0 / Dexamethasone 20, AL-Amyloidosis, cycle 3-6. (PID2457)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 1-2 (PID2452)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, cycle 3-6 (PID2453)Daratumumab 1800 / Lenalidomide 5 / Dexamethasone 20, AL Amyloidosis, Cycle 7+ (PID2454)Daratumumab 1800, maintenance after Dexamethasone (20/20/40) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3 - Daratumumab 1800 maintenance, AL amyloidosis, cycle 7+ (PID1633)Dexamethasone (20/20) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3, AL amyloidosis, cycle 1-2 (PID1631)Dexamethasone (20/20/40) / Cyclophosphamide 300 / Daratumumab 1800 / Bortezomib 1.3, AL Amyloidosis, cycle 3-6 (PID1632)Dexamethasone 20 / Bendamustine 100, AL-Amyloidosis (PID1513)Dexamethasone 20 / Bortezomib 1.3, AL Amyloidosis (PID1511)Dexamethasone 20 / Cyclophosphamide 350 / Bortezomib 1.0, AL amyloidosis (PID1514)Dexamethasone 20 / Melphalan 0.15 / Lenalidomide 10, AL Amyloidosis (PID1512)Dexamethasone 20 / Melphalan 0.22, AL-Amyloidosis (PID1506)Dexamethasone 20 / Melphalan 16, AL Amyloidosis (PID1508)Dexamethasone 40 / Melphalan 0.22 / Bortezomib 1.3, AL amyloidosis, cycle 1-2 (PID1638)Dexamethasone 40 / Melphalan 0.22 / Bortezomib 1.3, AL amyloidosis, cycle 3-8 (PID1639)Ixazomib 4 / Dexamethasone 20, AL-Amyloidosis (PID2534)Ixazomib 4 / Lenalidomide 15 / Dexamethasone 40, AL-Amyloidosis (PID2477)
